Glomus jugulare tumors are hypervascular tumors located in or near the temporal bone. They are initially slow-growing and asymptomatic but will eventually grow and invade the neck and surrounding structures. The tumor is more common in women in the fifth to sixth decades of life, though Glomus tumors can develop at any age. The higher prevalence in women is not precisely determined, but hormonal factors may play a role. Hormonal changes during pregnancy and post-menopause could contribute to this higher prevalence. Environmental factors, such as exposure to X-rays, chemicals, and radioactive materials, may also contribute to the increased prevalence in women. Additionally, genetic factors are relevant, as studies have shown a higher prevalence of Glomus tumors in certain families and individuals with a positive family history.
This retrospective cohort study included 61 patients. The findings demonstrated that preoperative embolization with PVA is an effective method to reduce vascular blush size before surgery. There were no considerable complications after the procedure, and pain after embolization was reported in only 18% of patients, indicating that the procedure is safe.
As mentioned, these tumors grow and invade adjacent structures, necessitating resection. Due to their hypervascular nature, patients are at risk of dangerous bleeding during surgery. Pre-surgical measures, such as intra-arterial embolization and radiotherapy, are employed to reduce bleeding during resection. During embolization, injecting embolizing agents (such as PVA, glue, and gelfoam) into feeding arteries decreases blood flow through the lesion. This reduces the risk of intraoperative bleeding and other complications, shortens operation time, and increases the surgeon’s control over the procedure. Improved control allows the surgeon to excise the lesion more completely, reducing the risk of recurrence (
8,
16,
23-
28).
We demonstrated a statistically significant reduction in vascular blush size among patients, which could suggest a lower bleeding tendency during surgery. However, confirming this assumption requires exact intraoperative bleeding volume measurement, which was unfortunately not performed in the current study. Additionally, the negative correlation between age and the mean percentage of vascular blush size reduction could be a warning for surgeons to pay closer attention to intraoperative bleeding tendencies in older patients, despite preoperative embolization.
The positive and clinically significant correlation between primary size and the percentage of blush size reduction is an encouraging finding for surgeons to consider embolization before surgery, even for large lesions.
Similar previous studies have shown consistent results. Helal et al. studied 29 patients with a mean tumor size of 3.4 cm. They reported at least a 50% reduction in tumor blush in 86.2% of patients, with none experiencing cranial nerve neuropathy. Near-total or total resection during surgery was achieved in 44.8% of patients. The average intraoperative blood loss was 888 cc, and 31% of patients required blood product transfusion during surgery (
29).
In another similar study, no patients experienced severe complications after embolization and surgery. Additionally, tumor blush completely disappeared after embolization in 83.3% of patients. In this series, 69.2% of patients showed histological evidence of tumor necrosis after resection (
16).
In summary, the results of this study indicate that embolization of Glomus jugulare tumors is a safe and effective method.
Our study has several limitations. First, the study design is a retrospective cohort, which typically lacks a control group. This limits the ability to establish causal relationships or compare the outcomes of embolization with alternative treatments or non-interventional approaches. Second, some patients were not candidates for surgery, and embolization was considered the main treatment for them. In these cases, the results of long-term embolization would be important. Our study lacks such information as all patients were candidates for immediate surgery. Potentially useful long-term outcome information, such as tumor recurrence rates and the durability and effectiveness of embolization over the long term, could not be determined in our study. Third, the study included a relatively small sample size of 61 patients. The findings may not be representative of the broader population of patients with Glomus jugulare tumors, and the generalizability of the results to other settings or populations may be limited. A fourth limitation is the lack of exact bleeding volume measurement during surgery. Additionally, we did not assess the ease of surgery by the surgeons, which is important. Finally, the lack of access to immediate and long-term post-surgery follow-up data (such as hemoglobin levels, recurrence rates, and other clinical parameters) that can determine the success of the final results is another limitation of the current study.
In conclusion, the findings of the current study suggest that intra-arterial embolization for Glomus jugular tumors could be safe and technically successful. The reduction in vascular blush size suggests that the procedure could effectively reduce bleeding during immediate surgery after embolization. However, caution is warranted due to the inherent limitations of the study, including its retrospective design, lack of long-term follow-up, and absence of a control group for comparison. Future studies employing prospective designs with long-term follow-up and including control groups are needed to validate these findings and provide more robust evidence. These efforts will contribute to further elucidating the effectiveness and safety of intra-arterial embolization in the management of Glomus jugular tumors.